Monitoring Universal Health Coverage (UHC) in high Tuberculosis burden countries: Tuberculosis mortality an important tracer of UHC service coverage
Autoři:
Michael Reid aff001; Glenna Roberts aff002; Eric Goosby aff001; Paul Wesson aff001
Působiště autorů:
University of California, San Francisco, School of Medicine, San Francisco, California, United States of America
aff001; University of California, San Francisco, Institute for Global Health Sciences, San Francisco, California, United States of America
aff002; University of California, San Francisco, Center of AIDS Prevention Studies, San Francisco, California, United States of America
aff003
Vyšlo v časopise:
PLoS ONE 14(10)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0223559
Souhrn
Background
There is a paucity of empiric data evaluating whether Tuberculosis (TB) is a useful surrogate measure for Universal Health Coverage (UHC), despite recognition of the importance of TB control efforts as part of the broader UHC agenda. We hypothesized that indicators of TB burden and coverage are sensitive tracers of UHC, when compared to other disease-specific indicators of service provision.
Methods
Linear regression models were used to determine the extent to which variability in UHC Service Coverage Index (SCI) was accounted for by (1) TB incidence rates and (2) TB mortality rates across 183 countries. Dominance analyses, stratifying countries by World Bank income criteria and TB burden, were used to determine the importance of TB treatment coverage in predicting UHC SCI scores, relative to other disease-specific indicators of service provision.
Results
Across 183 countries, TB incidence rate and TB mortality rate were negatively correlated, with UHC SCI score, (r = -0.67 and r = -0.74, respectively). In linear regression models including all 183 countries, TB incidence rates explained 45% of the variability in SCI scores; TB mortality rate explained 55% of variability. Restricting models to the 30 highest TB burden countries, both incidence and mortality explained less of the variability in SCI score (16% and 36%, respectively). In dominance analysis, comparing 13 disease-specific indicators of service provision, TB effective treatment coverage, ranked ninth overall. In dominance analysis stratified by TB burden, the TB treatment coverage estimate was ranked ninth in the 30 high burden countries and sixth in the 153 non-high burden countries. In separate analyses stratified by world bank income status, TB coverage ranked as third most important variable in LICs and fifth in LMICs and UMICs, but was less important in analysis restricted HICs (ranked seventh).
Conclusions
Compared to other disease-specific indicators of service provision, TB coverage was an important indicator of overall UHC service coverage, especially in low-income countries. These findings highlight that national-level inequities in TB-coverage may be an important tracer of universal health coverage.
Klíčová slova:
Death rates – Tuberculosis – Public and occupational health – Socioeconomic aspects of health – Finance – Blood counts – Global health
Zdroje
1. WHO WB. Tracking universal health coverage: first global monitoring report. Geneva: World Health Organization; 2015 [Available from: http://apps.who.int/iris/bitstream/handle/10665/174536/9789241564977_eng.pdf?sequence=1.
2. Reich MR, Harris J, Ikegami N, Maeda A, Cashin C, Araujo EC, et al. Moving towards universal health coverage: lessons from 11 country studies. Lancet. 2016;387(10020):811–6. doi: 10.1016/S0140-6736(15)60002-2 26299185
3. Stenberg K, Hanssen O, Edejer TT, Bertram M, Brindley C, Meshreky A, et al. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Glob Health. 2017;5(9):e875–e87. doi: 10.1016/S2214-109X(17)30263-2 28728918
4. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382(9908):1898–955. doi: 10.1016/S0140-6736(13)62105-4 24309475
5. Hogan DR, Stevens GA, Hosseinpoor AR, Boerma T. Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services. Lancet Glob Health. 2018;6(2):e152–e68. doi: 10.1016/S2214-109X(17)30472-2 29248365
6. Jamison DT, Alwan A, Mock CN, Nugent R, Watkins D, Adeyi O, et al. Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition. Lancet. 2018;391(10125):1108–20. doi: 10.1016/S0140-6736(17)32906-9 29179954
7. Watkins DA, Yamey G, Schaferhoff M, Adeyi O, Alleyne G, Alwan A, et al. Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health. Lancet. 2018;392(10156):1434–60. doi: 10.1016/S0140-6736(18)32389-4 30343859
8. WHO. Global tuberculosis report 2018 Geneva, Switzerland: WHO; 2018 [updated 2018. Available from: http://www.who.int/tb/publications/global_report/en/.
9. Participants at the Bellagio Workshop on Implementing Pro-Poor Universal Health C, Bump J, Cashin C, Chalkidou K, Evans D, Gonzalez-Pier E, et al. Implementing pro-poor universal health coverage. Lancet Glob Health. 2016;4(1):e14–6. doi: 10.1016/S2214-109X(15)00274-0 26700794
10. Bank W. World Bank Country and Lending Groups.
11. Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods. 2003;8(2):129–48. 12924811
12. Bank. WhOatIBfRaDW. Tracking universal health coverage: 2017 global monitoring report. 2017.
13. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet. 2019;393(10178):1331–84. doi: 10.1016/S0140-6736(19)30024-8 30904263
14. Hagiya H, Koyama T, Zamami Y, Minato Y, Tatebe Y, Mikami N, et al. Trends in incidence and mortality of tuberculosis in Japan: a population-based study, 1997–2016. Epidemiology and infection. 2018:1–10.
15. Pedrazzoli D, Borghi J, Viney K, Houben R, Lonnroth K. Measuring the economic burden for TB patients in the End TB Strategy and Universal Health Coverage frameworks. Int J Tuberc Lung Dis. 2019;23(1):5–11. doi: 10.5588/ijtld.18.0318 30674374
16. Gwatkin DR, Ergo A. Universal health coverage: friend or foe of health equity? Lancet. 2011;377(9784):2160–1. doi: 10.1016/S0140-6736(10)62058-2 21084113
17. Jamison DT, Alwan A, Mock CN, Nugent R, Watkins D, Adeyi O, et al. Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition. Lancet. 2017.
18. WHO. Implementing the end TB strategy: the essentials. Geneva: WHO; 2015/2016. Report No.: WHO/HTM/TB/2015.31.
19. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiologic reviews. 2001;23(2):288–301. doi: 10.1093/oxfordjournals.epirev.a000807 12192738
20. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet. 2010;375(9728):1814–29. doi: 10.1016/S0140-6736(10)60483-7 20488524
21. Gomes MGM, Oliveira JF, Bertolde A, Ayabina D, Nguyen TA, Maciel EL, et al. Introducing risk inequality metrics in tuberculosis policy development. Nat Commun. 2019;10(1):2480. doi: 10.1038/s41467-019-10447-y 31171791
22. Creswell J, Jaramillo E, Lonnroth K, Weil D, Raviglione M. Tuberculosis and poverty: what is being done. Int J Tuberc Lung Dis. 2011;15(4):431–2. doi: 10.5588/ijtld.10.0654 21396198
Článok vyšiel v časopise
PLOS One
2019 Číslo 10
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study
- Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
- Experimentally validated simulation of coronary stents considering different dogboning ratios and asymmetric stent positioning
- Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis